CRISHIGH SIGNALFINANCIAL10-K

Curis experienced substantial improvement in operating losses and net losses while facing a dramatic 75% decline in cash position to just $5.1 million.

The company's operating performance improved meaningfully with substantially reduced losses, but the severe cash depletion creates immediate liquidity concerns. The removal of specific cash runway guidance that previously extended into Q4 2025, combined with the precarious cash position, suggests potential near-term financing needs or operational constraints.

Comparing 2026-03-24 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

Curis showed mixed financial performance with revenue growing modestly to $9.9 million and R&D expenses increasing to $18.0 million, while operating and net losses improved substantially year-over-year. However, the company's cash position declined dramatically from $20.0 million to $5.1 million, representing a 75% decrease that significantly constrains financial flexibility. The reduction in total liabilities by 69% suggests debt restructuring or settlement activities, but the overall financial picture is dominated by the concerning cash depletion despite improved operating metrics.

FINANCIAL STATEMENT CHANGES
Operating Income
P&L
+87.2%
-$44.5M→-$5.7M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Net Income
P&L
+82.5%
-$43.4M→-$7.6M

Net income grew 82.5% — bottom-line growth signals improving overall business health.

Cash & Equivalents
Balance Sheet
-74.7%
$20.0M→$5.1M

Cash declined 74.7% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Current Assets
Balance Sheet
-73.8%
$26.4M→$6.9M

Current assets declined 73.8% — monitor working capital adequacy and short-term liquidity.

Total Liabilities
Balance Sheet
-69.3%
$47.3M→$14.5M

Liabilities reduced 69.3% — deleveraging improves balance sheet strength and financial flexibility.

Total Assets
Balance Sheet
-51.6%
$41.3M→$20.0M

Total assets contracted 51.6% — asset sales, write-downs, or balance sheet optimization underway.

R&D Expense
P&L
+31.8%
$13.7M→$18.0M

R&D investment increased 31.8% — signals commitment to future product development, though near-term margin impact.

Revenue
P&L
+31.5%
$7.5M→$9.9M

Strong top-line growth of 31.5% — accelerating demand or successful expansion into new markets.

Operating Cash Flow
Cash Flow
+31.2%
-$39.6M→-$27.2M

Operating cash flow surged 31.2% — exceptional cash generation, highest quality earnings signal.

Current Liabilities
Balance Sheet
-26%
$19.0M→$14.1M

Current liabilities reduced — improved short-term financial position and working capital health.

LANGUAGE CHANGES
NEW — 2026-03-24
PRIOR — 2025-03-31
ADDED
As of March 20, 2026, there were 39,978,693 shares of the registrant s common stock outstanding.
3 Table o f Contents Other Information Unless otherwise indicated, or unless the context of the discussion requires otherwise, we use the terms we, us, our and similar references to refer to Curis, Inc.
4 Table o f Contents Risk Factor Summary Investment in our securities involves risk.
If we fail to maintain compliance with Nasdaq Capital Market s listing requirements, our common stock could be delisted from trading, which would decrease the liquidity of our common stock and our ability to raise additional capital.
BUSINESS Overview We are a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase, or IRAK4 and FMS-like tyrosine kinase 3 or FLT3.
+7 more — sign up free →
REMOVED
As of March 27, 2025, there were 8,487,818 shares of the registrant s common stock outstanding.
Other Information Unless otherwise indicated, or unless the context of the discussion requires otherwise, we use the terms we, us, our and similar references to refer to Curis, Inc.
The alleged events of default, or any future allegations of an event of default, under the Oberland Purchase Agreement could have a material adverse effect on our business, financial condition and stock price, including our ability to continue as a going concern.
As of December 31, 2024, we had $20.0 million in cash and cash equivalents.
In March 2025, we completed a registered direct offering and concurrent private placement for net proceeds of approximately $9.0 million.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →